<?xml version="1.0" encoding="UTF-8"?>
<ref id="R55">
 <label>55</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <string-name>
    <surname>Siva</surname>
    <given-names>S</given-names>
   </string-name>, 
   <string-name>
    <surname>Bressel</surname>
    <given-names>M</given-names>
   </string-name>, 
   <string-name>
    <surname>Murphy</surname>
    <given-names>DG</given-names>
   </string-name>, 
   <etal>et al</etal>
  </person-group>. 
  <article-title>Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial</article-title>. 
  <source>Eur Urol</source>
  <year>2018</year>;
  <volume>74</volume>:
  <fpage>455</fpage>â€“
  <lpage>62</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.eururo.2018.06.004</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30227924?>
  <pub-id pub-id-type="pmid">30227924</pub-id>
 </mixed-citation>
</ref>
